News Medical on MSN23h
New CAR T-cell therapy shows promise against aggressive HER2+ breast cancer
One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast ...
Novel CAR T-cell therapy demonstrates efficacy and safety in preclinical models of HER2-positive solid tumors
One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast ...
Neuroscience News7d
CAR T-Cell Therapy Recruits Brain’s Defenses Against Glioblastoma
Researchers have developed an innovative CAR T-cell therapy to combat glioblastoma, the most common malignant brain tumor in ...
News Medical on MSN2d
Engineered SNIPRs transform CAR T-cell precision for safer cancer therapy
Researchers developed SNIPRs, innovative receptors that sense soluble ligands, enabling precise therapeutic control in CAR ...
Targeted Oncology5d
Real-World CAR T-Cell Therapy Outcomes in DLBCL Reveal Challenges and Disparities
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...
Glioblastoma: New treatment uses CAR-T cells to attack brain tumors from multiple angles
Glioblastoma is the most common kind of malignant brain tumor in adults. So far, no treatment has been able to make this ...
Frontiers11d
Interdisciplinary Innovations in CAR T Cell Therapy for Autoimmune and Cancer Treatment
The collection seeks to address key questions, such as the construction and design of CAR T cell receptors, the practical aspects of screening and manufacturing CAR therapies, and the feasibility of ...
Business Insider28d
Interius BioTherapeutics Doses First Patient with in vivo Chimeric Antigen Receptor (CAR) Gene Therapy for B-cell Malignancies
INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate CAR-T and CAR-NK cells in the patient’s body to target CD20-expressing malignant B cells Interim ...
Medscape19d
Outpatient CAR T: Safe, Effective, Accessible
A growing body of research suggests that clinicians can offer chimeric antigen receptor (CAR) T-cell therapy safely and effectively on an outpatient basis — a positive development as clinicians ...
Yahoo Finance28d
Interius BioTherapeutics Doses First Patient with in vivo Chimeric Antigen Receptor (CAR) Gene Therapy for B-cell Malignancies
a first-in-class gene therapy that delivers a CAR transgene to generate effector CAR-T and CAR-NK cells in vivo for the targeting of CD20-positive B cells for the treatment of B-cell malignancies.